ea0081rc2.6 | Rapid Communications 2: Adrenal and Cardiovascular Endocrinology 1 | ECE2022
Rees Aled
, Merke Deborah P
, Arlt Wiebke
, Brac De La Periere Aude
, Linden Hirschberg Angelica
, Juul Anders
, Mallappa Ashwini
, Newell-Price John D. C.
, Graham Perry Colin
, Prete Alessandro
, Reisch Nicole
, Stikkelbroeck Monica
, Touraine Philippe A
, Coope Helen
, Porter John
, Ross Richard John M
Background: The therapeutic goal in CAH is androgen control on the lowest achievable glucocorticoid dose, preferably an adrenal replacement dose (15-25 mg hydrocortisone a day)1. However, the glucocorticoid dose required to control androgens frequently exceeds that required for adrenal replacement2. Modified-release hydrocortisone (MRHC) capsules, (Efmody, Diurnal Ltd, Cardiff, UK), replicate cortisol diurnal rhythm and improve CAH control compared to sta...